• Surface Antigene Expression on White Blood Cells in CML Patients under Interferon Therapy, Onkologie, 14 (Supl. 2), 1991, 91.

U.B. Wandl, M. Nagel-Hiemke, D. May, E. Kreuzfelder, O. Kloke, T. Moritz, M. Kranzhoff, C. Anders, S. Seeber, N. Niederle:

• Antinuclear antibodies befor and during interferon treatment in patients with myeloproliferative disease, Blood, 78, 10 1991, 91

U.B. Wandl, N. Niederle, M. Kranzhoff, S.Seeber: Clonogenic Assay is not predictive but reflects therapeutic efficacy of interferons in the treatment of chronic myelogenous leukemia, Int. J. Cell Cloning 10, 1992, 292 – 298

U.B. Wandl, M. Nagel-Hiemke, D. May, E. Kreuzfelder, O. Kloke, M. Kranzhoff, S. Seeber, N. Niederle: Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders, Clin.Imunol. Immunopath, 65, 1992, 70 – 74

A.M. Beer, H. Kuhlemann, M. Kranzhoff: Naturheilverfahren und konventionelle Medizin bei ausgewählten Magen-Darm-Erkrankungen, Natura Med, 15, 2000, 18 – 26

M. Kranzhoff, A.M. Beer: Reizdarm-Syndrom: Es bieten sich zahlreiche therapeutische Optionen. Natura Med 7, 2004, 6 – 9

Acknowledgements:

U.B. Wandl, K. Günzel, R. Kath, M.E. Scheulen, J. Hayungs, K. Höffken, S. Seeber, N. Niederle: Treatment of high-risk, nonseminomatous testicular cancer with cisplatin, ifosfamide and bleomycin: Long-term results, Annal Oncol, 3, 1992, 123 -126

B. Opalka, U.B. Wandl, R. Becher, O. Kloke, M. Nagel-Hiemke, T. Moritz, U. Beer, S. Seeber, N. Niederle: Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alpha-2b alone or in combination with interferon gamma: Blood, 78, 9, 1991, 2188 – 2193